English
Regional settings| Spread | 3.62 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ €5,000.00 Short position overnight fee ~ €4,000.00 | -0.022091% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ €5,000.00 Short position overnight fee ~ €4,000.00 | -0.000132% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | EUR | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | France | ||||
| Commission on trade1 | 0% |
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 351.93 |
| Open | 353.93 |
| 1-Year Change | 20.59% |
| Day's Range | 346.44 - 355.92 |
Virbac SA is a France-based veterinarian pharmaceutical company that specializes in the development and production of vaccines and medicines for domestic animals and livestock. Its production centers are located in France, Australia, the United States, Mexico, Vietnam, Brazil and South Africa. Its development efforts focus mainly on formulating drugs designed to prevent or cure certain animal diseases. Its product portfolio encompasses pet medications such as pest control drugs, vaccines, antibiotics, anesthetics, anti-inflammatory drugs, mouth/dental care products, ophthalmologic and dermatological products intended for dogs, cats, horses, birds and rodents, as well as livestock medications including pest control drugs and antibiotics intended for cattle, sheep, pigs and poultry. It also offers food and electronic identification chips for pets.
BRIEF: For the six months ended 30 June 2021, Virbac SA revenues increased 11% to EUR529.4M. Net income applicable to common stockholders increased 54% to EUR72.7M. Revenues reflect Food Producting Animals segment increase of 14% to EUR215.9M, Companion Animals segment increase of 6% to EUR300.6M, Europe (excluding France) segment increase of 18% to EUR142.3M, Asia segment increase of 24% to EUR90.9M.
